EMERALD-1

NCT03778957 📎

Regimen

Experimental
TACE + durvalumab + bevacizumab (primary combo); TACE + durvalumab alone (second active arm)
Control
TACE + placebo

Population

Unresectable, embolisation-eligible hepatocellular carcinoma

Key finding

mPFS 15.0 vs 8.2 mo (HR 0.77, P=0.032) for durva+bev+TACE vs TACE alone. Durva-alone+TACE arm did not beat placebo. First phase 3 to validate IO+anti-VEGF + TACE triplet in intermediate-stage HCC.

Source: PMID 39798579

Timeline

    Guideline citations

    • NCCN HCC (p.59)